<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35157004</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>23</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">2168-6157</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>79</Volume>
            <Issue>4</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Apr</Month>
              <Day>01</Day>
            </PubDate>
          </JournalIssue>
          <Title>JAMA neurology</Title>
          <ISOAbbreviation>JAMA Neurol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Antiseizure Medication Concentrations During Pregnancy: Results From the Maternal Outcomes and Neurodevelopmental Effects of Antiepileptic Drugs (MONEAD) Study.</ArticleTitle>
        <Pagination>
          <StartPage>370</StartPage>
          <EndPage>379</EndPage>
          <MedlinePgn>370-379</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2021.5487</ELocationID>
        <Abstract>
          <AbstractText Label="IMPORTANCE">During pregnancy in women with epilepsy, lower blood concentrations of antiseizure medications can have adverse clinical consequences.</AbstractText>
          <AbstractText Label="OBJECTIVE">To characterize pregnancy-associated concentration changes for several antiseizure medications among women with epilepsy.</AbstractText>
          <AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS">Enrollment in this prospective, observational cohort study, Maternal Outcomes and Neurodevelopmental Effects of Antiepileptic Drugs (MONEAD), occurred from December 19, 2012, to February 11, 2016, at 20 US sites. Enrolled cohorts included pregnant women with epilepsy and nonpregnant control participants with epilepsy. Inclusion criteria were women aged 14 to 45 years, an intelligence quotient greater than 70 points, and, for the cohort of pregnant women, a fetal gestational age younger than 20 weeks. A total of 1087 women were assessed for eligibility; 397 were excluded and 230 declined. Data were analyzed from May 1, 2014, to June 30, 2021.</AbstractText>
          <AbstractText Label="EXPOSURE">Medication plasma concentrations in women taking monotherapy or in combination with noninteracting medications. The cohort of pregnant women was monitored through 9 months post partum, with similar time points for control participants.</AbstractText>
          <AbstractText Label="MAIN OUTCOMES AND MEASURES">Dose-normalized concentrations were calculated as total or unbound plasma medication concentrations divided by total daily dose. Phlebotomy was performed during 4 pregnancy study visits and 3 postpartum visits for the pregnant women and 7 visits over 18 months for control participants. The primary hypothesis was to test pregnancy changes of dose-normalized concentrations from nonpregnant postpartum samples compared with those of control participants.</AbstractText>
          <AbstractText Label="RESULTS">Of the 351 pregnant women and 109 control participants enrolled in MONEAD, 326 pregnant women (median [range] age, 29 [19-43] years) and 104 control participants (median [range] age, 29 [16-43] years) met eligibility criteria for this analysis. Compared with postpartum values, dose-normalized concentrations during pregnancy were decreased by up to 56.1% for lamotrigine (15.60 μg/L/mg to 6.85 μg/L/mg; P &lt; .001), 36.8% for levetiracetam (11.33 μg/L/mg to 7.16 μg/L/mg; P &lt; .001), 17.3% for carbamazepine (11.56 μg/L/mg to 7.97 μg/L/mg; P = .03), 32.6% for oxcarbazepine (11.55 μg/L/mg to 7.79 μg/L/mg; P &lt; .001), 30.6% for unbound oxcarbazepine (6.15 μg/L/mg to 4.27 μg/L/mg; P &lt; .001), 39.9% for lacosamide (26.14 μg/L/mg to 15.71 μg/L/mg; P &lt; .001), and 29.8% for zonisamide (40.12 μg/L/mg to 28.15 μg/L/mg; P &lt; .001). No significant changes occurred for unbound carbamazepine, carbamazepine-10,11-epoxide, and topiramate, although a decrease was observed for topiramate (29.83 μg/L/mg to 13.77 μg/L/mg; P = .18). Additionally, compared with dose-normalized concentrations from control participants, pregnancy dose-normalized median (SE) concentrations decreased significantly by week of gestational age: carbamazepine, -0.14 (0.06) μg/L/mg (P = .02); carbamazepine unbound, -0.04 (0.01) μg/L/mg (P = .01); lacosamide, -0.23 (0.07) μg/L/mg (P &lt; .001); lamotrigine, -0.20 (0.02) μg/L/mg (P &lt; .001); levetiracetam, -0.06 (0.03) μg/L/mg (P = .01); oxcarbazepine, -0.14 (0.04) μg/L/mg (P &lt; .001); oxcarbazepine unbound, -0.11 (0.03) μg/L/mg (P &lt; .001); and zonisamide, -0.53 (0.14) μg/L/mg (P &lt; .001) except for topiramate (-0.35 [0.20] μg/L/mg per week) and carbamazepine-10,11-epoxide (0.02 [0.01] μg/L/mg).</AbstractText>
          <AbstractText Label="CONCLUSIONS AND RELEVANCE">Study results suggest that therapeutic drug monitoring should begin early in pregnancy and that increasing doses of these anticonvulsants may be needed throughout the course of pregnancy.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Pennell</LastName>
            <ForeName>Page B</ForeName>
            <Initials>PB</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Karanam</LastName>
            <ForeName>Ashwin</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Experimental and Clinical Pharmacology, University of Minnesota College of Pharmacy, Minneapolis.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Meador</LastName>
            <ForeName>Kimford J</ForeName>
            <Initials>KJ</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Palo Alto, California.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gerard</LastName>
            <ForeName>Elizabeth</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Northwestern University, Chicago, Illinois.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kalayjian</LastName>
            <ForeName>Laura</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, University of Southern California, Los Angeles.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Penovich</LastName>
            <ForeName>Patricia</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Minnesota Epilepsy Group, St Paul.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Matthews</LastName>
            <ForeName>Abigail</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>The Emmes Company, Rockville, Maryland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>McElrath</LastName>
            <ForeName>Thomas M</ForeName>
            <Initials>TM</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Obstetrics and Gynecology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Birnbaum</LastName>
            <ForeName>Angela K</ForeName>
            <Initials>AK</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Experimental and Clinical Pharmacology, University of Minnesota College of Pharmacy, Minneapolis.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <CollectiveName>MONEAD Study Group</CollectiveName>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>U01 NS038455</GrantID>
            <Acronym>NS</Acronym>
            <Agency>NINDS NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>U01 NS050659</GrantID>
            <Acronym>NS</Acronym>
            <Agency>NINDS NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>U01 NS038455</GrantID>
            <Acronym>NS</Acronym>
            <Agency>NINDS NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D064888">Observational Study</PublicationType>
          <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>JAMA Neurol</MedlineTA>
        <NlmUniqueID>101589536</NlmUniqueID>
        <ISSNLinking>2168-6149</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000927">Anticonvulsants</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0H73WJJ391</RegistryNumber>
          <NameOfSubstance UI="D000077236">Topiramate</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>33CM23913M</RegistryNumber>
          <NameOfSubstance UI="D002220">Carbamazepine</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>44YRR34555</RegistryNumber>
          <NameOfSubstance UI="D000077287">Levetiracetam</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>459384H98V</RegistryNumber>
          <NameOfSubstance UI="D000078305">Zonisamide</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>563KS2PQY5</RegistryNumber>
          <NameOfSubstance UI="D000078334">Lacosamide</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>U3H27498KS</RegistryNumber>
          <NameOfSubstance UI="D000077213">Lamotrigine</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>VZI5B1W380</RegistryNumber>
          <NameOfSubstance UI="D000078330">Oxcarbazepine</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000927" MajorTopicYN="Y">Anticonvulsants</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002220" MajorTopicYN="N">Carbamazepine</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004827" MajorTopicYN="Y">Epilepsy</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000078334" MajorTopicYN="N">Lacosamide</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000077213" MajorTopicYN="N">Lamotrigine</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000077287" MajorTopicYN="N">Levetiracetam</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000078330" MajorTopicYN="N">Oxcarbazepine</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011247" MajorTopicYN="N">Pregnancy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000077236" MajorTopicYN="N">Topiramate</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000078305" MajorTopicYN="N">Zonisamide</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement><b>Conflict of Interest Disclosures:</b> Dr Pennell reported receiving research support from the National Institutes of Health and the Karger Foundation; honoraria for grant reviews from Harvard Medical School and the National Institutes of Health; advisory board honorarium from Harvard School of Public Health; speaking honoraria and/or travel reimbursements from the American Epilepsy Society and American Academy of Neurology; and royalties from UpToDate Inc. Dr Karanam reported being employed by Pfizer Inc during the conduct of the study, and his work on this study was during graduate school at the University of Minnesota. Dr Meador reported receiving research support from the National Institutes of Health, Eisai, Sunovion, and Medtronic Inc; receiving university payment for research consultant time from The Epilepsy Study Consortium related to Eisai, GW Pharmaceuticals, NeuroPace, Novartis, Supernus, Upsher-Smith Laboratories, UCB Pharma, and Vivus Pharmaceuticals; being a coinvestigator and director of Cognitive Core of the Human Epilepsy Project for the Epilepsy Study Consortium; and being on the editorial boards for <i>Neurology</i>, <i>Cognitive and Behavioral Neurology</i>, <i>Epilepsy &amp; Behavior</i>, and <i>Epilepsy &amp; Behavior Case Reports</i>. Dr Gerard reported receiving research support from Xenon and Sunovion Pharmaceuticals and speaking honoraria from GW Pharmaceuticals and Neurology Week. Dr Penovich reported receiving support for participation in speakers bureaus and on advisory boards for Neurelis, SK Biopharmaceuticals, UCB Pharma, and for advisory work for Lvis Corporation and Engage Therapeutics; and receiving personal fees from Greenwich Biosciences, Eisai, and Sunovian outside the submitted work. Dr McElrath reported receiving research support from the National Institutes of Health, NxPrenatal Inc, and Mirvie Inc; receiving compensation for service on the scientific advisory boards of NxPrenatal Inc, Mirvie Inc, Hoffman-LaRoache Ltd, and Momenta Pharmaceuticals Inc; and being a paid consultant for Comanche Biopharma Inc. Dr McElrath reported receiving royalties from UpToDate Inc. Dr Birnbaum reported receiving research support from the National Institutes of Health, Epilepsy Foundation, Supernus Pharmaceuticals, and Veloxis Pharmaceuticals and being a coinventor of a patent for intravenous carbamazepine (Lundbeck Pharmaceuticals). No other disclosures were reported.</CoiStatement>
      <InvestigatorList>
        <Investigator ValidYN="Y">
          <LastName>Cohen</LastName>
          <ForeName>Morris</ForeName>
          <Initials>M</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Druzin</LastName>
          <ForeName>Maurice</ForeName>
          <Initials>M</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Finnell</LastName>
          <ForeName>Richard</ForeName>
          <Initials>R</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Holmes</LastName>
          <ForeName>Gregory</ForeName>
          <Initials>G</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Nelson</LastName>
          <ForeName>Lorene</ForeName>
          <Initials>L</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Stowe</LastName>
          <ForeName>Zachary</ForeName>
          <Initials>Z</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Van Marter</LastName>
          <ForeName>Linda</ForeName>
          <Initials>L</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Wells</LastName>
          <ForeName>Peter</ForeName>
          <Initials>P</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Yerby</LastName>
          <ForeName>Mark</ForeName>
          <Initials>M</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Moore</LastName>
          <ForeName>Eugene</ForeName>
          <Initials>E</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>May</LastName>
          <ForeName>Ryan</ForeName>
          <Initials>R</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Ippolito</LastName>
          <ForeName>Dominic</ForeName>
          <Initials>D</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Brown</LastName>
          <ForeName>Carrie</ForeName>
          <Initials>C</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Robalino</LastName>
          <ForeName>Chelsea</ForeName>
          <Initials>C</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Skinner</LastName>
          <ForeName>Julia</ForeName>
          <Initials>J</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Davis</LastName>
          <ForeName>Lisa</ForeName>
          <Initials>L</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Shah</LastName>
          <ForeName>Nilay</ForeName>
          <Initials>N</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Leung</LastName>
          <ForeName>Brenda</ForeName>
          <Initials>B</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Friedman</LastName>
          <ForeName>Mark</ForeName>
          <Initials>M</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Loblein</LastName>
          <ForeName>Hayley</ForeName>
          <Initials>H</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Sheer</LastName>
          <ForeName>Traci</ForeName>
          <Initials>T</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Strickland</LastName>
          <ForeName>Suzanne</ForeName>
          <Initials>S</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Latif</LastName>
          <ForeName>Erin</ForeName>
          <Initials>E</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Park</LastName>
          <ForeName>Yong</ForeName>
          <Initials>Y</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Acosta-Cotte</LastName>
          <ForeName>Delmaris</ForeName>
          <Initials>D</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Ray</LastName>
          <ForeName>Patty</ForeName>
          <Initials>P</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Pack</LastName>
          <ForeName>Alison</ForeName>
          <Initials>A</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Cleary</LastName>
          <ForeName>Kirsten</ForeName>
          <Initials>K</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Echo</LastName>
          <ForeName>Joyce</ForeName>
          <Initials>J</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Zygmunt</LastName>
          <ForeName>Annette</ForeName>
          <Initials>A</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Casadei</LastName>
          <ForeName>Camilla</ForeName>
          <Initials>C</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Gedzelman</LastName>
          <ForeName>Evan</ForeName>
          <Initials>E</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Dolan</LastName>
          <ForeName>Mary</ForeName>
          <Initials>M</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Ono</LastName>
          <ForeName>Kim</ForeName>
          <Initials>K</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Bearden</LastName>
          <ForeName>Donald</ForeName>
          <Initials>D</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Ghilian</LastName>
          <ForeName>Christine</ForeName>
          <Initials>C</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Teagarden</LastName>
          <ForeName>Diane</ForeName>
          <Initials>D</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Newman</LastName>
          <ForeName>Melanee</ForeName>
          <Initials>M</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>McCabe</LastName>
          <ForeName>Paul</ForeName>
          <Initials>P</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Paglia</LastName>
          <ForeName>Michael</ForeName>
          <Initials>M</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Taylor</LastName>
          <ForeName>Cora</ForeName>
          <Initials>C</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Delucca</LastName>
          <ForeName>Rosemarie</ForeName>
          <Initials>R</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Blessing</LastName>
          <ForeName>Kristina</ForeName>
          <Initials>K</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Voinescu</LastName>
          <ForeName>Paula Emanuela</ForeName>
          <Initials>PE</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Boyer</LastName>
          <ForeName>Katrina</ForeName>
          <Initials>K</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Hanson</LastName>
          <ForeName>Ellen</ForeName>
          <Initials>E</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Young</LastName>
          <ForeName>Amy</ForeName>
          <Initials>A</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Hickey</LastName>
          <ForeName>Paige</ForeName>
          <Initials>P</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Strauss</LastName>
          <ForeName>Jolie</ForeName>
          <Initials>J</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Madeiros</LastName>
          <ForeName>Hayley</ForeName>
          <Initials>H</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Chen</LastName>
          <ForeName>Li</ForeName>
          <Initials>L</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Allien</LastName>
          <ForeName>Stephanie</ForeName>
          <Initials>S</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Sheldon</LastName>
          <ForeName>Yvonne</ForeName>
          <Initials>Y</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Weinau</LastName>
          <ForeName>Taylor</ForeName>
          <Initials>T</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Barkley</LastName>
          <ForeName>Gregory L</ForeName>
          <Initials>GL</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Spanaki-Varelas</LastName>
          <ForeName>Marianna</ForeName>
          <Initials>M</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Thomas</LastName>
          <ForeName>Andrea</ForeName>
          <Initials>A</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Constantinou</LastName>
          <ForeName>Jules</ForeName>
          <Initials>J</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Mahmood</LastName>
          <ForeName>Nazin</ForeName>
          <Initials>N</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Wasade</LastName>
          <ForeName>Vibhangini</ForeName>
          <Initials>V</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Gaddam</LastName>
          <ForeName>Shailaja</ForeName>
          <Initials>S</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Zillgitt</LastName>
          <ForeName>Andrew</ForeName>
          <Initials>A</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Anwar</LastName>
          <ForeName>Taimur</ForeName>
          <Initials>T</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Sandles</LastName>
          <ForeName>Carla</ForeName>
          <Initials>C</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Holmes</LastName>
          <ForeName>Theresa</ForeName>
          <Initials>T</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Johnson</LastName>
          <ForeName>Emily</ForeName>
          <Initials>E</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Krauss</LastName>
          <ForeName>Gregory</ForeName>
          <Initials>G</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Lawson</LastName>
          <ForeName>Shari</ForeName>
          <Initials>S</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Pritchard</LastName>
          <ForeName>Alison</ForeName>
          <Initials>A</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Ryan</LastName>
          <ForeName>Matthew</ForeName>
          <Initials>M</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Coe</LastName>
          <ForeName>Pam</ForeName>
          <Initials>P</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Hanna</LastName>
          <ForeName>Julie</ForeName>
          <Initials>J</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Reger</LastName>
          <ForeName>Katie</ForeName>
          <Initials>K</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Pohlman</LastName>
          <ForeName>Jenny</ForeName>
          <Initials>J</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Olson</LastName>
          <ForeName>Alisha</ForeName>
          <Initials>A</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>French</LastName>
          <ForeName>Jacqueline</ForeName>
          <Initials>J</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Schweizer</LastName>
          <ForeName>William</ForeName>
          <Initials>W</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Morrison</LastName>
          <ForeName>Chris</ForeName>
          <Initials>C</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>MacAllister</LastName>
          <ForeName>William</ForeName>
          <Initials>W</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Clements</LastName>
          <ForeName>Tobi</ForeName>
          <Initials>T</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Hwang</LastName>
          <ForeName>Sean</ForeName>
          <Initials>S</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Tam</LastName>
          <ForeName>Hima Bindu</ForeName>
          <Initials>HB</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Cukier</LastName>
          <ForeName>Yael</ForeName>
          <Initials>Y</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Meltzer</LastName>
          <ForeName>Erica</ForeName>
          <Initials>E</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Helcer</LastName>
          <ForeName>Jacqueline</ForeName>
          <Initials>J</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Lau</LastName>
          <ForeName>Connie</ForeName>
          <Initials>C</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Grobman</LastName>
          <ForeName>William</ForeName>
          <Initials>W</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Coda</LastName>
          <ForeName>Joseph</ForeName>
          <Initials>J</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Miller</LastName>
          <ForeName>Emily</ForeName>
          <Initials>E</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Bellinski</LastName>
          <ForeName>Irena</ForeName>
          <Initials>I</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Bachman</LastName>
          <ForeName>Elizabeth</ForeName>
          <Initials>E</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Krueger</LastName>
          <ForeName>Casey</ForeName>
          <Initials>C</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Seliger</LastName>
          <ForeName>Jordan</ForeName>
          <Initials>J</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>DeWolfe</LastName>
          <ForeName>Jennifer</ForeName>
          <Initials>J</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Owen</LastName>
          <ForeName>John</ForeName>
          <Initials>J</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Thompson</LastName>
          <ForeName>Matthew</ForeName>
          <Initials>M</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Hall</LastName>
          <ForeName>Cheryl</ForeName>
          <Initials>C</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Labiner</LastName>
          <ForeName>David</ForeName>
          <Initials>D</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Maciulla</LastName>
          <ForeName>James</ForeName>
          <Initials>J</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Moon</LastName>
          <ForeName>Jennifer</ForeName>
          <Initials>J</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Darris</LastName>
          <ForeName>Kayla</ForeName>
          <Initials>K</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Cavitt</LastName>
          <ForeName>Jannifer</ForeName>
          <Initials>J</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Privitera</LastName>
          <ForeName>Michael</ForeName>
          <Initials>M</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Flood-Schaffer</LastName>
          <ForeName>Kellie</ForeName>
          <Initials>K</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Jewell</LastName>
          <ForeName>George</ForeName>
          <Initials>G</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Mendoza</LastName>
          <ForeName>Lucy</ForeName>
          <Initials>L</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Serrano</LastName>
          <ForeName>Enrique</ForeName>
          <Initials>E</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Salih</LastName>
          <ForeName>Yasin</ForeName>
          <Initials>Y</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Bermudez</LastName>
          <ForeName>Christin</ForeName>
          <Initials>C</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Miranda</LastName>
          <ForeName>Michelle</ForeName>
          <Initials>M</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Velez-Ruiz</LastName>
          <ForeName>Naymee</ForeName>
          <Initials>N</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Figueredo</LastName>
          <ForeName>Pedro</ForeName>
          <Initials>P</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Bagic</LastName>
          <ForeName>Anto</ForeName>
          <Initials>A</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Urban</LastName>
          <ForeName>Alexandra</ForeName>
          <Initials>A</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Gedela</LastName>
          <ForeName>Satya</ForeName>
          <Initials>S</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Patterson</LastName>
          <ForeName>Christina</ForeName>
          <Initials>C</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Jeyabalan</LastName>
          <ForeName>Arundhathi</ForeName>
          <Initials>A</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Radonovich</LastName>
          <ForeName>Krestin</ForeName>
          <Initials>K</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Sutcliffe</LastName>
          <ForeName>Melissa</ForeName>
          <Initials>M</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Beers</LastName>
          <ForeName>Susan</ForeName>
          <Initials>S</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Wiles</LastName>
          <ForeName>Carrie</ForeName>
          <Initials>C</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Alhaj</LastName>
          <ForeName>Sandra</ForeName>
          <Initials>S</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Stek</LastName>
          <ForeName>Alice</ForeName>
          <Initials>A</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Perez</LastName>
          <ForeName>Sonia</ForeName>
          <Initials>S</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Sierra</LastName>
          <ForeName>Rachel</ForeName>
          <Initials>R</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Tsai</LastName>
          <ForeName>Jeffrey</ForeName>
          <Initials>J</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Miller</LastName>
          <ForeName>John W</ForeName>
          <Initials>JW</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Mao</LastName>
          <ForeName>Jennie</ForeName>
          <Initials>J</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Phatak</LastName>
          <ForeName>Vaishali</ForeName>
          <Initials>V</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Kim</LastName>
          <ForeName>Michelle</ForeName>
          <Initials>M</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Cheng-Hakimian</LastName>
          <ForeName>Andrea</ForeName>
          <Initials>A</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>DeNoble</LastName>
          <ForeName>Gina</ForeName>
          <Initials>G</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Sam</LastName>
          <ForeName>Maria</ForeName>
          <Initials>M</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Parker</LastName>
          <ForeName>Lamar</ForeName>
          <Initials>L</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Morris</LastName>
          <ForeName>Melissa</ForeName>
          <Initials>M</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Dimos</LastName>
          <ForeName>Jessica</ForeName>
          <Initials>J</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Miller</LastName>
          <ForeName>Danielle</ForeName>
          <Initials>D</Initials>
        </Investigator>
      </InvestigatorList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pmc-release">
          <Year>2023</Year>
          <Month>2</Month>
          <Day>14</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>14</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>14</Day>
          <Hour>12</Hour>
          <Minute>15</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35157004</ArticleId>
        <ArticleId IdType="pmc">PMC8845026</ArticleId>
        <ArticleId IdType="doi">10.1001/jamaneurol.2021.5487</ArticleId>
        <ArticleId IdType="pii">2789145</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Fiest KM, Sauro KM, Wiebe S, et al. . Prevalence and incidence of epilepsy: a systematic review and meta-analysis of international studies. Neurology. 2017;88(3):296-303. doi:10.1212/WNL.0000000000003509</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0000000000003509</ArticleId>
            <ArticleId IdType="pmc">PMC5272794</ArticleId>
            <ArticleId IdType="pubmed">27986877</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Anderson GD. Pregnancy-induced changes in pharmacokinetics: a mechanistic-based approach. Clin Pharmacokinet. 2005;44(10):989-1008. doi:10.2165/00003088-200544100-00001</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2165/00003088-200544100-00001</ArticleId>
            <ArticleId IdType="pubmed">16176115</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pennell PB, Peng L, Newport DJ, et al. . Lamotrigine in pregnancy: clearance, therapeutic drug monitoring, and seizure frequency. Neurology. 2008;70(22, pt 2):2130-2136. doi:10.1212/01.wnl.0000289511.20864.2a</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/01.wnl.0000289511.20864.2a</ArticleId>
            <ArticleId IdType="pmc">PMC3589527</ArticleId>
            <ArticleId IdType="pubmed">18046009</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Voinescu PE, Park S, Chen LQ, et al. . Antiepileptic drug clearances during pregnancy and clinical implications for women with epilepsy. Neurology. 2018;91(13):e1228-e1236. doi:10.1212/WNL.0000000000006240</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0000000000006240</ArticleId>
            <ArticleId IdType="pmc">PMC6161546</ArticleId>
            <ArticleId IdType="pubmed">30185446</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Reisinger TL, Newman M, Loring DW, Pennell PB, Meador KJ. Antiepileptic drug clearance and seizure frequency during pregnancy in women with epilepsy. Epilepsy Behav. 2013;29(1):13-18. doi:10.1016/j.yebeh.2013.06.026</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.yebeh.2013.06.026</ArticleId>
            <ArticleId IdType="pmc">PMC3775962</ArticleId>
            <ArticleId IdType="pubmed">23911354</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Harden CL, Pennell PB, Koppel BS, et al. ; American Academy of Neurology; American Epilepsy Society . Management issues for women with epilepsy--focus on pregnancy (an evidence-based review): III. vitamin K, folic acid, blood levels, and breast-feeding: report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Epilepsia. 2009;50(5):1247-1255. doi:10.1111/j.1528-1167.2009.02130.x</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1528-1167.2009.02130.x</ArticleId>
            <ArticleId IdType="pubmed">19507305</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Giri N, Agarwal S, Shaik N, Pan G, Chen Y, Elmquist WF. Substrate-dependent breast cancer resistance protein (Bcrp1/Abcg2)-mediated interactions: consideration of multiple binding sites in in vitro assay design. Drug Metab Dispos. 2009;37(3):560-570. doi:10.1124/dmd.108.022046</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1124/dmd.108.022046</ArticleId>
            <ArticleId IdType="pmc">PMC2680510</ArticleId>
            <ArticleId IdType="pubmed">19056916</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Reimers A, Helde G, Bråthen G, Brodtkorb E. Lamotrigine and its N2-glucuronide during pregnancy: the significance of renal clearance and estradiol. Epilepsy Res. 2011;94(3):198-205. doi:10.1016/j.eplepsyres.2011.02.002</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.eplepsyres.2011.02.002</ArticleId>
            <ArticleId IdType="pubmed">21356585</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ohman I, Beck O, Vitols S, Tomson T. Plasma concentrations of lamotrigine and its 2-N-glucuronide metabolite during pregnancy in women with epilepsy. Epilepsia. 2008;49(6):1075-1080. doi:10.1111/j.1528-1167.2007.01471.x</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1528-1167.2007.01471.x</ArticleId>
            <ArticleId IdType="pubmed">18076642</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Karanam A, Pennell PB, French JA, et al. . Lamotrigine clearance increases by 5 weeks gestational age: relationship to estradiol concentrations and gestational age. Ann Neurol. 2018;84(4):556-563. doi:10.1002/ana.25321</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ana.25321</ArticleId>
            <ArticleId IdType="pubmed">30168175</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tran TA, Leppik IE, Blesi K, Sathanandan ST, Remmel R. Lamotrigine clearance during pregnancy. Neurology. 2002;59(2):251-255. doi:10.1212/WNL.59.2.251</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.59.2.251</ArticleId>
            <ArticleId IdType="pubmed">12136066</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Battino D, Tomson T, Bonizzoni E, et al. ; EURAP Study Group . Seizure control and treatment changes in pregnancy: observations from the EURAP epilepsy pregnancy registry. Epilepsia. 2013;54(9):1621-1627. doi:10.1111/epi.12302</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/epi.12302</ArticleId>
            <ArticleId IdType="pubmed">23848605</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Berlin M, Barchel D, Gandelman-Marton R, et al. . Therapeutic levetiracetam monitoring during pregnancy: “mind the gap”. Ther Adv Chronic Dis. 2019;10:2040622319851652. doi:10.1177/2040622319851652</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/2040622319851652</ArticleId>
            <ArticleId IdType="pmc">PMC6540481</ArticleId>
            <ArticleId IdType="pubmed">31191874</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Westin AA, Reimers A, Helde G, Nakken KO, Brodtkorb E. Serum concentration/dose ratio of levetiracetam before, during and after pregnancy. Seizure. 2008;17(2):192-198. doi:10.1016/j.seizure.2007.11.027</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.seizure.2007.11.027</ArticleId>
            <ArticleId IdType="pubmed">18180176</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tomson T, Palm R, Källén K, et al. . Pharmacokinetics of levetiracetam during pregnancy, delivery, in the neonatal period, and lactation. Epilepsia. 2007;48(6):1111-1116. doi:10.1111/j.1528-1167.2007.01032.x</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1528-1167.2007.01032.x</ArticleId>
            <ArticleId IdType="pubmed">17381438</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kuhnz W, Jäger-Roman E, Rating D, et al. . Carbamazepine and carbamazepine-10,11- epoxide during pregnancy and postnatal period in epileptic mother and their nursed infants: pharmacokinetics and clinical effects. Pediatr Pharmacol (New York). 1983;3(3-4):199-208.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">6677873</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tomson T, Lindbom U, Ekqvist B, Sundqvist A. Disposition of carbamazepine and phenytoin in pregnancy. Epilepsia. 1994;35(1):131-135. doi:10.1111/j.1528-1157.1994.tb02922.x</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1528-1157.1994.tb02922.x</ArticleId>
            <ArticleId IdType="pubmed">8112235</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tomson T, Lindbom U, Ekqvist B, Sundqvist A. Epilepsy and pregnancy: a prospective study of seizure control in relation to free and total plasma concentrations of carbamazepine and phenytoin. Epilepsia. 1994;35(1):122-130. doi:10.1111/j.1528-1157.1994.tb02921.x</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1528-1157.1994.tb02921.x</ArticleId>
            <ArticleId IdType="pubmed">8112234</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Battino D, Binelli S, Bossi L, et al. . Plasma concentrations of carbamazepine and carbamazepine 10,11-epoxide during pregnancy and after delivery. Clin Pharmacokinet. 1985;10(3):279-284. doi:10.2165/00003088-198510030-00007</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2165/00003088-198510030-00007</ArticleId>
            <ArticleId IdType="pubmed">4017398</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Johnson EL, Stowe ZN, Ritchie JC, et al. . Carbamazepine clearance and seizure stability during pregnancy. Epilepsy Behav. 2014;33:49-53. doi:10.1016/j.yebeh.2014.02.011</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.yebeh.2014.02.011</ArticleId>
            <ArticleId IdType="pmc">PMC4040964</ArticleId>
            <ArticleId IdType="pubmed">24632353</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yerby MS, Friel PN, Miller DQ. Carbamazepine protein binding and disposition in pregnancy. Ther Drug Monit. 1985;7(3):269-273. doi:10.1097/00007691-198507030-00005</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/00007691-198507030-00005</ArticleId>
            <ArticleId IdType="pubmed">4049462</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bernus I, Hooper WD, Dickinson RG, Eadie MJ. Metabolism of carbamazepine and co-administered anticonvulsants during pregnancy. Epilepsy Res. 1995;21(1):65-75. doi:10.1016/0920-1211(95)00012-Y</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0920-1211(95)00012-Y</ArticleId>
            <ArticleId IdType="pubmed">7641678</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Christensen J, Sabers A, Sidenius P. Oxcarbazepine concentrations during pregnancy: a retrospective study in patients with epilepsy. Neurology. 2006;67(8):1497-1499. doi:10.1212/01.wnl.0000240047.11166.0e</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/01.wnl.0000240047.11166.0e</ArticleId>
            <ArticleId IdType="pubmed">17060586</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wegner I, Edelbroek P, de Haan GJ, Lindhout D, Sander JW. Drug monitoring of lamotrigine and oxcarbazepine combination during pregnancy. Epilepsia. 2010;51(12):2500-2502. doi:10.1111/j.1528-1167.2010.02771.x</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1528-1167.2010.02771.x</ArticleId>
            <ArticleId IdType="pubmed">21204816</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mazzucchelli I, Onat FY, Ozkara C, et al. . Changes in the disposition of oxcarbazepine and its metabolites during pregnancy and the puerperium. Epilepsia. 2006;47(3):504-509. doi:10.1111/j.1528-1167.2006.00459.x</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1528-1167.2006.00459.x</ArticleId>
            <ArticleId IdType="pubmed">16529613</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Westin AA, Nakken KO, Johannessen SI, Reimers A, Lillestølen KM, Brodtkorb E. Serum concentration/dose ratio of topiramate during pregnancy. Epilepsia. 2009;50(3):480-485. doi:10.1111/j.1528-1167.2008.01776.x</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1528-1167.2008.01776.x</ArticleId>
            <ArticleId IdType="pubmed">19178558</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ohman I, Sabers A, de Flon P, Luef G, Tomson T. Pharmacokinetics of topiramate during pregnancy. Epilepsy Res. 2009;87(2-3):124-129. doi:10.1016/j.eplepsyres.2009.08.004</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.eplepsyres.2009.08.004</ArticleId>
            <ArticleId IdType="pubmed">19740626</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Reimers A, Helde G, Becser Andersen N, et al. . Zonisamide serum concentrations during pregnancy. Epilepsy Res. 2018;144:25-29. doi:10.1016/j.eplepsyres.2018.05.002</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.eplepsyres.2018.05.002</ArticleId>
            <ArticleId IdType="pubmed">29751353</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Irody. Irody home page. Accessed January 15, 2012. http://www.irody.com</Citation>
        </Reference>
        <Reference>
          <Citation>Subramanian M, Birnbaum AK, Remmel RP. High-speed simultaneous determination of nine antiepileptic drugs using liquid chromatography-mass spectrometry. Ther Drug Monit. 2008;30(3):347-356. doi:10.1097/FTD.0b013e3181678ecb</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/FTD.0b013e3181678ecb</ArticleId>
            <ArticleId IdType="pubmed">18520607</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pennell PB, French JA, May RC, et al. ; MONEAD Study Group . Changes in seizure frequency and antiepileptic therapy during pregnancy. N Engl J Med. 2020;383(26):2547-2556. doi:10.1056/NEJMoa2008663</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa2008663</ArticleId>
            <ArticleId IdType="pmc">PMC7919187</ArticleId>
            <ArticleId IdType="pubmed">33369356</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Meador KJ, Pennell PB, May RC, et al. ; MONEAD Investigator Group . Changes in antiepileptic drug-prescribing patterns in pregnant women with epilepsy. Epilepsy Behav. 2018;84:10-14. doi:10.1016/j.yebeh.2018.04.009</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.yebeh.2018.04.009</ArticleId>
            <ArticleId IdType="pmc">PMC6016834</ArticleId>
            <ArticleId IdType="pubmed">29730500</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tomson T, Battino D, Bonizzoni E, et al. ; EURAP Study Group . Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurol. 2018;17(6):530-538. doi:10.1016/S1474-4422(18)30107-8</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1474-4422(18)30107-8</ArticleId>
            <ArticleId IdType="pubmed">29680205</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hernández-Díaz S, Smith CR, Shen A, et al. ; North American AED Pregnancy Registry; North American AED Pregnancy Registry . Comparative safety of antiepileptic drugs during pregnancy. Neurology. 2012;78(21):1692-1699. doi:10.1212/WNL.0b013e3182574f39</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0b013e3182574f39</ArticleId>
            <ArticleId IdType="pubmed">22551726</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Meador KJ, Baker GA, Browning N, et al. ; NEAD Study Group . Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study. Lancet Neurol. 2013;12(3):244-252. doi:10.1016/S1474-4422(12)70323-X</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1474-4422(12)70323-X</ArticleId>
            <ArticleId IdType="pmc">PMC3684942</ArticleId>
            <ArticleId IdType="pubmed">23352199</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bromley RL, Baker GA. Fetal antiepileptic drug exposure and cognitive outcomes. Seizure. 2017;44:225-231. doi:10.1016/j.seizure.2016.10.006</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.seizure.2016.10.006</ArticleId>
            <ArticleId IdType="pubmed">27784632</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bromley RL, Calderbank R, Cheyne CP, et al. ; UK Epilepsy and Pregnancy Register . Cognition in school-age children exposed to levetiracetam, topiramate, or sodium valproate. Neurology. 2016;87(18):1943-1953. doi:10.1212/WNL.0000000000003157</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0000000000003157</ArticleId>
            <ArticleId IdType="pubmed">27581218</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shallcross R, Bromley RL, Cheyne CP, et al. ; Liverpool and Manchester Neurodevelopment Group; UK Epilepsy and Pregnancy Register . In utero exposure to levetiracetam vs valproate: development and language at 3 years of age. Neurology. 2014;82(3):213-221. doi:10.1212/WNL.0000000000000030</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0000000000000030</ArticleId>
            <ArticleId IdType="pubmed">24401687</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Meador KJ, Cohen MJ, Loring DW, et al. ; Maternal Outcomes and Neurodevelopmental Effects of Antiepileptic Drugs Investigator Group . Two-year-old cognitive outcomes in children of pregnant women with epilepsy in the maternal outcomes and neurodevelopmental effects of antiepileptic drugs study. JAMA Neurol. 2021;78(8):927-936. doi:10.1001/jamaneurol.2021.1583</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamaneurol.2021.1583</ArticleId>
            <ArticleId IdType="pmc">PMC8185630</ArticleId>
            <ArticleId IdType="pubmed">34096986</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tomson T, Battino D, Bonizzoni E, et al. ; EURAP Study Group . Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology. 2019;93(9):e831-e840. doi:10.1212/WNL.0000000000008001</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0000000000008001</ArticleId>
            <ArticleId IdType="pubmed">31391249</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen H, Yang K, Choi S, Fischer JH, Jeong H. Up-regulation of UDP-glucuronosyltransferase (UGT) 1A4 by 17beta-estradiol: a potential mechanism of increased lamotrigine elimination in pregnancy. Drug Metab Dispos. 2009;37(9):1841-1847. doi:10.1124/dmd.109.026609</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1124/dmd.109.026609</ArticleId>
            <ArticleId IdType="pmc">PMC2729326</ArticleId>
            <ArticleId IdType="pubmed">19546240</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tomson T, Battino D, Bromley R, et al. . Executive summary: management of epilepsy in pregnancy: a report from the International League Against Epilepsy Task Force on Women and Pregnancy. Epilepsia. 2019;60(12):2343-2345. doi:10.1111/epi.16395</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/epi.16395</ArticleId>
            <ArticleId IdType="pubmed">31763685</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Polepally AR, Pennell PB, Brundage RC, et al. . Model-based lamotrigine clearance changes during pregnancy: clinical implication. Ann Clin Transl Neurol. 2014;1(2):99-106. doi:10.1002/acn3.29</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/acn3.29</ArticleId>
            <ArticleId IdType="pmc">PMC4038031</ArticleId>
            <ArticleId IdType="pubmed">24883336</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
